

Title (en)
MULTIMERIC FC RECEPTOR POLYPEPTIDES INCLUDING A MODIFIED FC DOMAIN

Title (de)
MULTIMERE FC-REZEPTOR-POLYPEPTIDE MIT MODIFIZIERTER FC-DOMÄNE

Title (fr)
POLYPEPTIDES MULTIMERES DU RECEPTEUR FC COMPRENANT UN DOMAINE FC MODIFIE

Publication
EP 2099819 A4 20100317 (EN)

Application
EP 07845376 A 20071213

Priority
• AU 2006001890 W 20061213
• AU 2007001934 W 20071213
• US 76266407 A 20070613

Abstract (en)
[origin: WO2008070927A1] A soluble multimeric polypeptide or protein is disclosed that is able to inhibit interaction of leukocyte Fcγ receptors (FcγR) and immunoglobulin G (IgG). The protein or polypeptide comprises two or more Fc binding regions linked in a head to tail arrangement, at least one of which is derived from an FcγR type receptor, and an Fc domain of an immunoglobulin which has been modified to reduce or prevent binding to the said Fc binding regions and/ or to alter effector function. Also described are polynucleotide molecules encoding the polypeptide or protein and the use thereof in methods of treating a subject for an immune- complex (IC)-mediated inflammatory disease.

IPC 8 full level
C07K 14/35 (2006.01); **A61P 37/06** (2006.01); **C07K 14/47** (2006.01); **C07K 17/00** (2006.01); **C07K 19/00** (2006.01); **C12N 15/62** (2006.01)

CPC (source: EP US)
A61P 7/02 (2017.12 - EP); **A61P 7/04** (2017.12 - EP); **A61P 13/12** (2017.12 - EP); **A61P 19/02** (2017.12 - EP); **A61P 29/00** (2017.12 - EP); **A61P 37/06** (2017.12 - EP); **C07K 7/06** (2013.01 - EP); **C07K 14/705** (2013.01 - US); **C07K 14/70535** (2013.01 - EP US); **C07K 16/00** (2013.01 - EP); **C07K 2317/52** (2013.01 - EP); **C07K 2319/00** (2013.01 - US); **C07K 2319/30** (2013.01 - US); **C07K 2319/35** (2013.01 - US); **C07K 2319/70** (2013.01 - US); **C07K 2319/74** (2013.01 - US); **Y10S 530/868** (2013.01 - EP US)

Citation (search report)
• [A] WO 03010202 A1 20030206 - MEDEXGEN CO LTD [KR], et al
• [A] POWELL M S ET AL: "Investigation of FcγγRIIIa dimerization", FASEB JOURNAL, FED. OF AMERICAN SOC. FOR EXPERIMENTAL BIOLOGY, BETHESDA, MD, US, vol. 14, no. 6, 20 April 2000 (2000-04-20), pages A960, XP009111142, ISSN: 0892-6638
• [A] KURUCZ ISTVAN ET AL: "Bacterially expressed human FcγγRIIIb is soluble and functionally active after in vitro refolding", IMMUNOLOGY LETTERS, ELSEVIER BV, NL, vol. 75, no. 1, 1 December 2000 (2000-12-01), pages 33 - 40, XP002511480, ISSN: 0165-2478
• [A] IERINO F L ET AL: "RECOMBINANT SOLUBLE HUMAN FCGAMMARII: PRODUCTION, CHARACTERIZATION AND INHIBITION OF THE ARTHUS REACTION", THE JOURNAL OF EXPERIMENTAL MEDICINE, ROCKEFELLER UNIVERSITY PRESS, UNITED STATES, vol. 178, no. 5, 1 November 1993 (1993-11-01), pages 1617 - 1628, XP009015491, ISSN: 0022-1007
• See references of WO 2008070927A1

Designated contracting state (EPC)
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

DOCDB simple family (publication)
WO 2008070927 A1 20080619; BR PI0721078 A2 20141007; CA 2671732 A1 20080619; EP 2099819 A1 20090916; EP 2099819 A4 20100317; JP 2010512154 A 20100422; RU 2009126545 A 20110120

DOCDB simple family (application)
AU 2007001934 W 20071213; BR PI0721078 A 20071213; CA 2671732 A 20071213; EP 07845376 A 20071213; JP 2009540549 A 20071213; RU 2009126545 A 20071213